CN102206257B - Edwardsiella tarda immunogenic protective antigen, and related expression vector, vaccine and application - Google Patents

Edwardsiella tarda immunogenic protective antigen, and related expression vector, vaccine and application Download PDF

Info

Publication number
CN102206257B
CN102206257B CN 201110095826 CN201110095826A CN102206257B CN 102206257 B CN102206257 B CN 102206257B CN 201110095826 CN201110095826 CN 201110095826 CN 201110095826 A CN201110095826 A CN 201110095826A CN 102206257 B CN102206257 B CN 102206257B
Authority
CN
China
Prior art keywords
tarda
protective antigen
vaccine
edwardsiella tarda
blunt tarda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN 201110095826
Other languages
Chinese (zh)
Other versions
CN102206257A (en
Inventor
吴海珍
张萌
李小勇
沈斌兵
王启要
张元兴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
East China University of Science and Technology
Original Assignee
East China University of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by East China University of Science and Technology filed Critical East China University of Science and Technology
Priority to CN 201110095826 priority Critical patent/CN102206257B/en
Publication of CN102206257A publication Critical patent/CN102206257A/en
Application granted granted Critical
Publication of CN102206257B publication Critical patent/CN102206257B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Farming Of Fish And Shellfish (AREA)

Abstract

The invention provides an Edwardsiella tarda immunogenic protective antigen which is an Edwardsiella tarda flagellar related protein with an amino acid sequence expressed in SEQ ID NO:2 and a preferred nucleotide sequence expressed in SEQ ID NO:1, a recombination expression vector corresponding to the Edwardsiella tarda immunogenic protective antigen, an Edwardsiella tarda subunit vaccine prepared by the Edwardsiella tarda immunogenic protective antigen, and an application of the Edwardsiella tarda immunogenic protective antigen in the preparation of the Edwardsiella tarda subunit vaccine. The Edwardsiella tarda immunogenic protective antigen provided by the invention has a good immunogenicity and can be used for preparing a safe, effective and economic vaccine, thus has a high commercial value and is suitable for large scale popularization and application.

Description

Blunt tarda immune protective antigen, correlative expression vector, vaccine and application
Technical field
The present invention relates to the antigen technical field, more specifically, relate to the immune protective antigen technical field, refer to especially a kind of blunt tarda immune protective antigen, correlative expression vector, vaccine and application.
Background technology
Along with the continuous stable development of fishery cultivating, various disease problems become increasingly conspicuous, and cultured output and growth are caused have a strong impact on.In China, sudden, the explosive disease of the seawater cage culture that grew up in recent years and industrialized culture fish frequently occurs.At present, the average death loss rate of the sea farming of China is more than 30%, and annual financial loss reaches 16,000,000,000 yuan, and the disease problem has become the important factor that the restriction mariculture industry develops in a healthy way.
For the generation of various diseases, the chemotherapy take microbiotic as representative had once been brought into play active effect to control and the control of disease.But the environmental pollution that this disease measure of control cause, a large amount of appearance of anti-medicine cause of disease, the negative impacts such as drug residue of fishery products are on the rise.At European Union, America ﹠ Canada, disabled gradually in culture fishery take microbiotic as main chemicals.
be the day by day serious development trend of cultured fishes disease of containing that various environmental factorss and cultivation density surge etc. cause, advance the Sustainable development of mariculture industry, the World Food Programme is in conjunction with successful experience (the Ormonde P.Fisheries resources:trends in production of developed country's Fisheries Development, utilization and trade.In:Nomura I (ed.) .The State of World Fishery and Agriculture2002.Rome:FAO Information Division, 2002, p3-p45.), advocate " system management approach " (System management approaches, SMA) generation of the various diseases of aquaculture model prevention.Main contents in this measure are exactly to advocate the application of the various immune protection technology take vaccine inoculation as representative.The employing of these measures will greatly reduce the use of chemicals, both avoid the pollution to environment, increase again the consumption safety of fishery products.As the cost-effective strategies for disease prevention and control and the means that meet environmental friendliness, the strategy of sustainable development, vaccination is just becoming main forward position and the Application Areas of countries in the world research and development in modern aquaculture standard.
But pointed strong, the long lifetime immunity of disease-resistant cycle of vaccine, effect are significantly and control characteristics initiatively.Inactivated vaccine (Kill vaccine) take pathogenic bacteria cell deactivation body as base form is prevented and treated as aquiculture disease effective means is provided; but inactivated vaccine generally has the technology applied defect of administration inconvenience (drug administration by injection just has immune protective efficiency preferably); very inconvenience for the fish farming industry of the thousands of quantity of needs immunity, the administration cost often can not be born by culture fishery.And, for disease, serious fry and juvenile fish occuring can't implement drug administration by injection, simultaneously, to many disease inactivated vaccines poor effect or invalid often.Everything has brought obstruction all for the widespread use of aquatic products the farming disease harms immune protection technology.
The industrial character of culture fishery requires the necessary economy of disease control technology, application implementation conveniently.Therefore, the exploitation of vaccine product is except the technical requirements of high-titer, and immune cost must be cheap, can not exceed the ability to bear of aquaculture.Attenuated live vaccine because of have convenient drug administration (can soak administration), immunizing potency high (can reduce dosage), with low cost, can develop the new technology advantage of broad-spectrum vaccine (live bacterial vaccines often has intersecting protective), become focus and the Disciplinary Frontiers of the current vaccine research of used for aquiculture in the world and exploitation.
Edwardsiella is the common pathogenic agent of a class that causes fresh water, Principal Bacterial Diseases of Mariculture Fish, specifically be divided into blunt tarda (Edwardsiella tarda), catfish tarda (Edwardsiella ictaluri) and guarantor's section's tarda (Edwardsiella hoshinae).Be referred to as tarda disease (Edwardsiellosis) by its fish hueppe's disease that causes.It is wide that this disease is propagated area, and without obviously seasonal, infection rate and mortality ratio are high, and the kind of harm is many, and carp is arranged, tilapia, common eel, grey mullet, salmon, trout, the fingerling that the great majority such as flounder flounder have higher economic worth.In addition, blunt tarda also infects shellfish, reptiles, batrachians, birds, mammals.Merit attention, blunt tarda or a kind of important infecting both domestic animals and human cause of disease bacterium, it is the member of unique infection mankind in Edwardsiella.At present, the more serious pathogenic agent of the sick disease of China's cultured fishes tarda is mainly blunt tarda, and the grave danger that has the pathogenic agent of existing to shift to human body.United States Patent (USP) has and utilizes Rifampin screening to obtain the natural attenuation mutant of wild strain as report (the Evans J J of attenuated live vaccine, Klesius, P H and Shoemaker C A2006 Modifi ed live Edwardsiella tarda vaccine for aquatic animals; United States Patent7067122).There is no at present effective prophylactico-therapeutic measures of this disease in China.
separate in the sick fish body of the tarda disease that the wild strain EIB202 of blunt tarda of the present invention breaks out in China Area of The East China Sea cultivation fishing ground and obtain, a kind of supervirulent blunt tarda bacterial strain (Edwardsiella tarda EIB202, Xiao Jingfan etc., " Isolation and identification of fish pathogen Edwardsiella tarda from mariculture in China ", " Aquaculture Research " Vol.40, 2009), be deposited in Chinese Typical Representative culture collection center, address: Wuhan, China city Wuhan University, deposit number is: CCTCC NO:M 208068, preservation date is on May 1st, 2008, specifically referring to Chinese invention patent application CN200910052707.6.
Because blunt tarda pathogenesis is still lacked systematic understanding, its many hosts adaptability also causes the control of this bacterium particularly difficult.At present, the control of tarda disease mainly relies on antibiotic use, take chemotherapy as main.Because microbiotic can extensively be identified, their application in aquaculture more and more are restricted.In addition, the blunt tarda that causes a disease usually is found that multiple antibacterial element mixture is had natural resistance, has increased take the difficulty of microbiotic as the treatment on basis.By contrast, from a long-term viewpoint, vaccine is that disease is controlled safer more effective method.Due to the antigenicity of inactivated vaccine a little less than, and the security of attenuated vaccine is unstable, for this reason, develops easy to use, efficient, easy commercialization scale operation, effective subunit vaccine, and is particularly necessary to water industry.
Summary of the invention
Main purpose of the present invention is exactly the problems and shortcomings for above existence; a kind of blunt tarda immune protective antigen, correlative expression vector, vaccine and application are provided; this blunt tarda immune protective antigen immunogenicity is better; for the tarda disease of cultured fishes provides a kind of safety; effectively; economic vaccine has actual business development using value, is suitable for large-scale promotion application.
To achieve these goals; in a first aspect of the present invention; a kind of blunt tarda immune protective antigen is provided; be characterized in; described blunt tarda immune protective antigen is blunt tarda flagellum associated protein, and the aminoacid sequence of described blunt tarda flagellum associated protein is as shown in SEQ ID NO:2.
Preferably, the nucleotide sequence of described blunt tarda flagellum associated protein is as shown in SEQ ID NO:1.
In a second aspect of the present invention, a kind of recombinant expression vector is provided, be characterized in, comprise expression vector and be incorporated into the extraneous nucleotide sequence of the above-mentioned blunt tarda immune protective antigen of coding on described expression vector.
Preferably, described extraneous nucleotide sequence is as shown in SEQ ID NO:1.
In a third aspect of the present invention, a kind of subunit vaccine of blunt tarda is provided, be characterized in, be prepared from by above-mentioned blunt tarda immune protective antigen.
In a fourth aspect of the present invention, provide the above-mentioned application of blunt tarda immune protective antigen in the subunit vaccine of the blunt tarda of preparation.
Preferably, described blunt tarda is blunt tarda EIB202, and deposit number is: CCTCC NO:M 208068.
beneficial effect of the present invention specifically is: blunt tarda immune protective antigen of the present invention is blunt tarda flagellum associated protein, the aminoacid sequence of described blunt tarda flagellum associated protein is as shown in SEQ ID NO:2, experiment shows that this blunt tarda immune protective antigen has immanoprotection action preferably to blunt tarda, simultaneously, for the subunit vaccine exploitation, this blunt tarda immune protective antigen also will be as the preferred target spot of follow-up vaccine design, for the tarda disease of cultured fishes provides a kind of safety, effectively, economic vaccine, actual business development using value is arranged, be suitable for large-scale promotion application.
Description of drawings
Fig. 1 is the SDS-PAGE figure after a specific embodiment of the recombinant expression vector of the present invention blunt tarda immune protective antigen purifying of expressing, swimming lane 1: albumen Marker; Swimming lane 2 and 3:FD protein expression result; Swimming lane 4 and 5:FD protein purification result.
Fig. 2 is that the premunition protection after blunt tarda immune protective antigen immunity zebra fish of the present invention is analyzed.
Fig. 3 is that the premunition protection after blunt tarda immune protective antigen immunity turbot of the present invention is analyzed.
Fig. 4 is blunt tarda immune protective antigen immunity turbot serum sterilizing vigor of the present invention analysis.
Fig. 5 is specific antibody titres analysis in blunt tarda immune protective antigen immunity turbot serum of the present invention.
Embodiment
Content for a better understanding of the present invention is described further especially exemplified by following examples.
The preparation of embodiment 1 recombinant protein vaccine
One, experiment material
1, bacterial strain and plasmid
Intestinal bacteria Escherichia coli TOP10, intestinal bacteria E.coli BL21 (DE3) are available from TIANGEN Biotech (Beijing) Co., Ltd.; Blunt tarda E.tarda EIB202, preserving number is: CCTCC M 208068; PET 28a (+) carrier is available from precious biotechnology (Dalian) company limited.
2, substratum and culture condition
Substratum:
LB:1% Tryptone,0.5% Yeast extract,1% NaCl。Solid medium adds 2%ager.121 ℃ of autoclaving 20min.Being used for intestinal bacteria cultivates.
TSB:3% TSB。Solid medium adds 2% ager.121 ℃ of autoclaving 20min.Being used for EIB202 cultivates.
The DHL substratum: 60g deoxycholate hydrogen sulfide lactose agar substratum is dissolved in the 1L deionized water, repeatedly boils to be dissolved to clarification, and cooling rear making is dull and stereotyped.
Culture condition:
Intestinal bacteria shaking table concussion in the standing cultivation of 37 ℃ of LB solid medium middle plateforms or LB liquid nutrient medium is cultivated
Blunt tarda is inoculated in the TSB liquid nutrient medium, the jolting of spending the night of 28 ℃, 200r/min.Blunt tarda liquid is coated with or lines on the DHL solid medium, is inverted in incubated overnight in 37 ℃ of constant incubators, forms the translucent evil mind bacterium colony in edge on the DHL solid medium.
3, experiment reagent
Conventional molecular biology reagent and test kit are available from TIANGEN Biotech (Beijing) Co., Ltd.; Restriction enzyme Nde I, Xho I is available from precious biotechnology (Dalian) company limited.The conventional reagent of protein expression and purifying is available from Shanghai Sangon Biological Engineering Technology And Service Co., Ltd.Affinity chromatography medium Ni-Sepharose FF is available from GE Healthcare.The monoclonal antibody of the brill IgM of the Chinese People's Anti-Japanese Military and Political College is available from Aquatic Diagnostics, and the sheep anti mouse monoclonal antibody is available from Tiangen.
4, antigenic protein gene sequence
According to E.tarda EIB202 whole genome sequence, obtain the DNA sequence dna (SEQ ID NO:1) of corresponding blunt tarda flagellum associated protein FD gene.Its aminoacid sequence is seen SEQ ID NO:2.
5, antigen protein primer
With the Auele Specific Primer of Primer Premier 5 software design FD genes, primer is synthetic through Shanghai bio-engineering corporation, is the PAGE purified product.
FDf:GGGAGATCATATGGCCATTTCGGTATCG (Nde I)
FDr:GCCGCTCGAGTAAGATCTGGCGTACGT (Xho I)
6, laboratory animal and immunoreagent
Zebra fish is purchased from Shanghai plant, the long 4cm of body, and body weight is 0.4g approximately.First be placed in 2 weeks of aquarium endoadaptation handling before experiment, after move to the fish feeding system and adapted to for 2 weeks.Flow fish feeding system every day and change water body, cultivation temperature 22 ℃ of left and right.Feed 2 times and in time remove the ight soil residue every day.
Turbot is purchased from Weifang, Shandong plant, body weight 30g, and the long 10cm of body is placed in the tank endoadaptation and raised and train for 2 weeks, and is standby.In experiment, use natural sea-water to replace 2/3 volume aquaculture water and inflation, water temperature 14-16 ℃ every day.The immunization front and back are according to the cultivation program management of routine.
Fish is purchased from Sigma company with narcotic tricaine methanesulphonate (MS-222).Fish adjuvant MONTANIDE TMISA 763A buys the company in French SEPPIC.
Two, experimental technique
1, the structure of FD recombinant antigen protein gene
The extracting of vector plasmid pET28a is carried out according to the operation instructions of TIANprep Mini Plasmid Kit.Carry out the genomic extraction of blunt tarda EIB202 according to the operation instructions of TIANamp Bacteria DNA Kit.Genome is used for the PCR reaction, and the primer must arrive for the Auele Specific Primer FDf/FDr of design the purpose product that two ends contain Nde I and Xho I restriction enzyme digestion sites.Select restriction enzyme Nde I and Xho I to carry out double digestion, the goal gene after enzyme is cut and carrier, utilize sepharose DNA to reclaim test kit and reclaim DNA after the lower purpose band of cutting through agarose gel electrophoresis.
After obtaining the goal gene and plasmid with sticky end, under the effect of DNA ligase, both are coupled together, form the recombinant plasmid that contains goal gene.Recombinant plasmid namely can be used for turning clone's e. coli bl21 (DE3) Host Strains.Clone on flat board cuts through order-checking and enzyme and verifies and to be defined as the positive, is the recombination bacillus coli BL21 (DE3) of blunt tarda FD albumen/pET-28a-FD.
2, the expression and purification of FD recombinant antigen protein
The expression strain that order-checking is successful is inoculated, and grows into to a certain degree to add inductor IPTG to carry out abduction delivering.Collect the centrifugal rear supersonic method broken wall of using of bacterium liquid, centrifugal rear collection supernatant.Protein electrophoresis detects the FD recombinant protein of abduction delivering, sees shown in Fig. 1 arrow.The protein electrophoresis result shows that the FD recombinant protein has great expression.
A His mark respectively has been with at FD recombinant protein two ends, can be combined with Ni specifically.Therefore can come single-minded ground purification of target albumen with the Ni post.With the albumen that wash-out obtains, the molecular weight cut-off of packing into is in the dialysis tubing of 14kD, dialyse in PBS solution, and-70 ℃ of preservations.
Embodiment 2: the drug administration by injection immunoprotection test take zebra fish as experimental animal
Determination of protein concentration
Utilize nucleic acid quantification instrument NanoDrop ND-1000 spectrophotometer to detect its OD 280, determine recombinant protein concentration, with the PBS damping fluid, albumen is diluted to predetermined concentration.
The immunization of zebra fish
Purifying FD recombinant protein mixes according to the ratio of 7: 3 with adjuvant ISA 763A, and final protein concentration reaches 0.3 μ g/ μ l.The cultivation of zebra fish random packet, 30/group, every zebra fish carries out the tail muscles injecting immune.Then normally raise, observe activity and the death condition of fish.The immunity time is one month.Negative control is PBS and adjuvant mixing group.
Before injection operation, first zebra fish is soaked in 100ng/ml MS-222 and anaesthetizes.After finishing experimental period, will remain zebra fish and carry out euthanasia, namely be soaked in 300ng/ml MS-222 more than 10 minutes.
The poison of attacking of zebra fish is injected
Collect blunt tarda EIB202 thalline, with sterilization PBS washing three times, the cell density after resuspended with spectrophotometric determination, quantitatively OD 600Be 1, and with PBS, bacterium liquid be diluted to dense required degree gradient; Every the test zebra fish carries out the tail muscles injecting immune according to the dosage of 5 μ l/fish; Observed and recorded is respectively organized zebra fish morbidity and dead situation.
The mensuration of recombinant protein immune protective efficiency
After cultivating for 4 weeks after the zebra fish immunity, according to wild strain medium lethal dose LD50 value, select suitable dosage to attack the poison experiment to the zebra fish of immunity; Observed and recorded is respectively organized zebra fish morbidity and death condition.
Calculate relative protection ratio (Relative percent survival, RPS) by (1) formula:
RPS=(the 1-immune group rate of dying/control group mortality ratio) * 100% (1)
The death condition that zebra fish is attacked in malicious rear 8 days is seen Fig. 2.After zebra fish is attacked poison, first day has the minute quantity fish dead, and the fish body settles out subsequently.Began to have the situation of mortality on the 3rd day, and find that zebra fish is slowly movable, front afterbody swings on one's deathbed, infection site body colour blackout.Death condition tended towards stability in the 8th day.Wherein the mortality ratio of blank group is 81%, and the mortality ratio of immune group is 23%.Calculating learns, the relative protection ratio of FD albumen is 71%.
After being dissected, sick fish finds the enlargement of fish body spleen, the pinkiness of losing blood, and it is hemorrhage that dispersivity appears in liver.Be coated with the DHL plate after will sick fish tissue suitably processing dilution, 28 ℃ of incubated overnight have a large amount of evil mind bacterium colonies to exist on plate, illustrate that zebra fish is nosogenetic to have infected really blunt tarda.
Embodiment 3: the drug administration by injection immunoprotection test take turbot as experimental animal
The immunity of turbot
The cultivation of turbot random packet, 30/group, every dosage according to 100 μ l/fish carries out the tail muscles injection.After the purifying protein dialysed overnight, according to its concentration, be mixed to protein concentration with adjuvant ISA 763A according to the ratio of 7: 3 and reach 0.3 μ g/ μ l.PBS and the negative contrast of adjuvant ISA 763A immune group.Then normally raise, observe the movable of fish and have or not death.The immunity time was 10 weeks.
Before injection operation, first turbot is soaked in 100ng/ml MS-222 and anaesthetizes.After finishing experimental period, will remain turbot and carry out euthanasia, namely be soaked in 300ng/ml MS-222 more than 10 minutes.
Turbot attack poison
To attack malicious method in zebra fish identical for the poison of attacking of turbot, and turbot in the 10th week, according to wild strain LD50 value, selects suitable dosage to divide into groups to attack malicious the experiment to the turbot of immunity after immunity.
Antigen protein is the immune protective efficiency analysis in the turbot body
The death condition that turbot is attacked in malicious rear 8 days is seen Fig. 3.Experimental result shows, turbot is attacked after poison and to be begun to have the situation of mortality on the 3rd day, and obvious disease symptom is arranged: the gill cover edge of sick fish, and the subcutaneous hyperemia of film fin base portion and the outside of belly, rubescent, hemorrhage place's focus generation purulence ulcer, form subcutaneous abscess subsequently.Death condition tended towards stability in the 7th day.Wherein the mortality ratio of blank group is 80%, and the mortality ratio of immune group is 30%.Calculating learns, the relative protection ratio of FD albumen is 62.5%.
Compare the experimental result that zebra fish and turbot immunity FD albumen obtains; the candidate antigens albumen FD that on one-level animal model zebra fish, primary dcreening operation obtains is described; on secondary animal model turbot, immanoprotection action is preferably arranged also; this lays good basis for follow-up further multiple sieve experiment on the one hand, has confirmed that also zebra fish can become the new animal model of screening protective antigen.Simultaneously, for the subunit vaccine exploitation, FD also will be as the preferred target spot of follow-up vaccine design.
Embodiment 4:FD antigen protein immune level is analyzed
Turbot blood sampling and sero-fast preparation
After turbot immunity FD recombinant protein, respectively in the 8th week and the 10th week from experiment fish tail venous blood sampling, every tail taking-up is 0.3ml blood approximately.The whole blood room temperature is standing rear centrifugal, collects upper serum, be stored in-80 ℃ standby.
The antiserum(antisera) sterilization experiment
Inoculate blunt tarda EIB202, incubated overnight.With PBS washing three times, get a certain amount of bacteria suspension and mix with immune serum and hatch, in 1,2,3,4, the 5h spread plate of taking a sample respectively; The blank sample is that bacteria suspension mixes with NIS.Establish three groups of parallel controls for every group.All dull and stereotyped 20h that cultivate carry out enumeration, and calculate antiserum(antisera) at the sterilizing ability of different time points.With antiserum(antisera) and the EIB202 hatching that turbot immunity FD recombinant protein obtains, get the sero-fast sterilizing ability of different incubation period point analysiss.The results are shown in Figure 4.
By upper figure result as can be known, antiserum(antisera) and the hatching of blunt tarda are after 4 hours, and viable count is minimum, and namely this moment, serum had best sterilizing ability.After 4 hours, in the 8th all serum, the survival rate of blunt tarda is that the survival rate of bacterium in 41%, the 10 all serum is 53% with the viable bacteria hatching, and the antiserum(antisera) in obvious the 8th week has more bactericidal property.
The antibody level of serum determination and analysis
The specific antibody level that the immunity of experiment fish turbot produces is afterwards measured conventional indirect ELISA method and is detected:
The hatching of recombinant protein FD wrapper sheet after purifying is spent the night.Wash plate 3 times, pat dry; Add confining liquid solution, in 22 ℃ of sealing 2h.Wash plate 3 times, pat dry; Add the fish immune serum, 100 μ l/ holes are added in each hole with 2 times of serial dilution degree, and the Initial dilution degree is 1: 4, and greatest dilution is 1: 512, and blank serum is done same treatment in contrast.Hatch 3h in 22 ℃.Wash plate 5 times, pat dry; The monoclonal antibody that adds the brill IgM of the Chinese People's Anti-Japanese Military and Political College is hatched 1h in 22 ℃.Wash plate 5 times, pat dry; Add sheep anti mouse monoclonal antibody (HRP mark), hatch 1h in 22 ℃.Wash plate 5 times, pat dry; Add solvable type tmb substrate washing lotion, the room temperature lucifuge is placed 10min; Add reaction terminating liquid, be placed in microplate reader with OD 450Wavelength detects.
Antibody titer is determined according to the P/N value.Test serum absorbance (P)=serum OD value to be checked-blank serum OD value, negative control sera absorbance (N)=negative serum OD value-blank OD value, greater than 2.1 the time, sero-fast highly diluted multiple is its final antibody titer when both ratios.
Utilize that conventional indirect ELISA method measures that turbot immunity FD recombinant protein produces specific antibody level, the results are shown in Figure 5.Result shows that sero-fast light absorption value is obviously greater than blank serum.Produced certain specific antibody after turbot immunity FD recombinant protein.
In sum, blunt tarda immune protective antigen immunogenicity of the present invention is better, and for the tarda disease of cultured fishes provides a kind of safety, effectively, economic vaccine has actual business development using value, is suitable for large-scale promotion application.
In this specification sheets, the present invention is described with reference to its specific embodiment.But, still can make various modifications and conversion obviously and not deviate from the spirit and scope of the present invention.Therefore, specification sheets and accompanying drawing are regarded in an illustrative, rather than a restrictive.
Figure IDA0000055650200000011
Figure IDA0000055650200000031

Claims (3)

1. subunit vaccine that is used for the blunt tarda disease of fish; it is characterized in that; be prepared from by blunt tarda immune protective antigen; described blunt tarda immune protective antigen is blunt tarda flagellum associated protein, and the aminoacid sequence of described blunt tarda flagellum associated protein is as shown in SEQ ID NO:2.
2. a blunt tarda immune protective antigen is for the preparation of the application in the subunit vaccine of the blunt tarda diseases of fish; it is characterized in that; described blunt tarda immune protective antigen is blunt tarda flagellum associated protein, and the aminoacid sequence of described blunt tarda flagellum associated protein is as shown in SEQ ID NO:2.
3. application according to claim 2, is characterized in that, described blunt tarda is blunt tarda EIB202, and deposit number is: CCTCC NO:M208068.
CN 201110095826 2011-04-15 2011-04-15 Edwardsiella tarda immunogenic protective antigen, and related expression vector, vaccine and application Active CN102206257B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 201110095826 CN102206257B (en) 2011-04-15 2011-04-15 Edwardsiella tarda immunogenic protective antigen, and related expression vector, vaccine and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 201110095826 CN102206257B (en) 2011-04-15 2011-04-15 Edwardsiella tarda immunogenic protective antigen, and related expression vector, vaccine and application

Publications (2)

Publication Number Publication Date
CN102206257A CN102206257A (en) 2011-10-05
CN102206257B true CN102206257B (en) 2013-06-05

Family

ID=44695348

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 201110095826 Active CN102206257B (en) 2011-04-15 2011-04-15 Edwardsiella tarda immunogenic protective antigen, and related expression vector, vaccine and application

Country Status (1)

Country Link
CN (1) CN102206257B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105920593A (en) * 2016-06-08 2016-09-07 山东省海洋生物研究院 Edwardsiella tarda subunit oral microencapsule vaccine for aquatic product
CN106085903B (en) * 2016-06-08 2019-09-24 山东省海洋生物研究院 A kind of aquatic products Edwardsiella tarda
CN105920594A (en) * 2016-06-08 2016-09-07 类延乐 FliC protein microcapsule vaccine
CN116574166A (en) * 2023-05-04 2023-08-11 中国海洋大学 Bicistronic DNA vaccine of fish beta defensin and outer membrane protein C

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
flgD gene product [Edwardsiella tarda EIB202];Wang,Q.等;《NCBI database》;20110310;NCBI Reference Sequence: YP_003295281.1 *
Genome sequence of the versatile fish pathogen Edwardsiella tarda provides insights into its adaptation to broad host ranges and intracellular niches;Qiyao Wang 等;《PLoS ONE》;20091031;第4卷(第10期);e7646 *
Qiyao Wang 等.Genome sequence of the versatile fish pathogen Edwardsiella tarda provides insights into its adaptation to broad host ranges and intracellular niches.《PLoS ONE》.2009,第4卷(第10期),e7646.
Wang,Q.等.flgD gene product [Edwardsiella tarda EIB202].《NCBI database》.2011,NCBI Reference Sequence: YP_003295281.1.
张晓佩 等.迟钝爱德华氏菌鞭毛蛋白的提取与分析.《福建农业学报》.2008,第23卷(第1期),35-38.
迟钝爱德华氏菌鞭毛蛋白的提取与分析;张晓佩 等;《福建农业学报》;20081231;第23卷(第1期);35-38 *

Also Published As

Publication number Publication date
CN102206257A (en) 2011-10-05

Similar Documents

Publication Publication Date Title
CN102430120B (en) Adjuvant for enhancing fish vaccine immunization effect and application thereof
CN102988981B (en) Adjuvant for improving immunization effect of Edwardsiella vaccine and use method of adjuvant
CN103255089B (en) The strong malicious slow Edwardsiella vaccine strain of one strain and application thereof
CN104560851B (en) The preparation method and application of aeromonas salmonicida live vaccine preparation and freeze dried vaccine product
CN101342367B (en) Edwardsiella tarda attenuated live vaccine
CN105801707A (en) Oral vaccine for treating grass carp hemorrage as well as preparation and application thereof
CN102206257B (en) Edwardsiella tarda immunogenic protective antigen, and related expression vector, vaccine and application
CN108003240A (en) A kind of multi-joint antiidiotype Yolk antibody vaccine of mariculture fish and preparation method thereof
CN101629149B (en) Marker-free gene-deletion attenuated mutant strain derived from Edwardsiella tarda wild strain, related preparation and application thereof
CN104962572A (en) Preparation method for aeromonas hydrophila outer membrane protein gene prokaryotic expression protein
CN104628871A (en) Preparation of infectious bursal disease (IBD) protein engineering vaccine
CN100566752C (en) Fishes infectious spleen and kidney necrosis virus gene engineering vaccine and preparation method thereof
CN103014051B (en) Multiple-potency live vaccine for fish and application thereof
CN103275890A (en) Vibrio anguillarum (listonella anguillarum) virulent strain and application thereof
CN104961811A (en) Aeromonas hydrophila outer membrane protein gene prokaryotic expression protein and application thereof
CN1276076C (en) No mark gene deletion deoxidated mutant strain of wild Manhu bacteria and its use
CN102604993B (en) Immunologic adjuvant-Helicobacter pylori antigen fused protein oral vaccine and preparation method thereof
CN101974472B (en) Marker-free gene deletion attenuated mutant strain of Edwardsiella tarda wild strain as well as relevant preparations and application thereof
CN104093419B (en) The preparation method of the wide spectrum vaccine of prevention birds colibacillosis
CN103667145B (en) Edwardsiella tarda genetic engineering low virulent strain and its application
CN106047763A (en) Vibrio anguillarum O3 serotype bacterial strain and application thereof
CN105316252A (en) Five-gene-deleted streptococcus suis serotype 2 strain and application
CN109010816A (en) One kind killing the different vibrio vaccine of salmon and its application
CN101659958B (en) Multi-titer live vaccine as well as preparation method and application thereof
CN104208665B (en) A kind of Edwardsiella tarda subunit vaccine and its preparation method and application

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant